Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.72 |
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118210 | 0.88 | MET (0.66) | METJAK2ALK | |
| SCHEMBL29857891 | 0.85 | MET (0.60) | METJAK2 | |
| SCHEMBL26916667 | 0.85 | MET (0.60) | METJAK2 | |
| SCHEMBL26916664 | 0.85 | MET (0.60) | METJAK2 | |
| SCHEMBL29858200 | 0.85 | MET (0.60) | METJAK2 | |
| SCHEMBL26917044 | 0.85 | MET (0.60) | METJAK2 | |
| SCHEMBL3421973 | 0.85 | MET (0.77) | METJAK2ALK | |
| SCHEMBL29857933 | 0.84 | MET (0.68) | METJAK2ALK | |
| SCHEMBL26916848 | 0.84 | MET (0.68) | METJAK2ALK | |
| SCHEMBL26917127 | 0.84 | MET (0.68) | METJAK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119070-B | Selective JAK2 inhibitors and uses thereof | 华东理工大学 | 2023-02-17 | — | — | CN | disclosed |
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3782993-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | East China University of Science and Technology (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782993-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | East China University of Science and Technology (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019196937-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
| WO-2015034729-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014089324-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | JAK2, JAK1, JAK3 | MET 708/4885JAK2 1/4885ALK 2388/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885JAK2 8/4885ALK 54/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885JAK2 287/4885ALK 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.